SPEAKERS

Prof. Per Borghammer is a distinguished neuroscientist, professor, and senior consultant at the Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Denmark. As the chief responsible for clinical brain imaging and diagnostics, he has significantly advanced the understanding and application of neuroimaging techniques in the study of neurodegenerative diseases, particularly Parkinson’s disease. A leader in the field, Dr. Borghammer’s research focuses on the development of innovative PET and MRI methodologies to investigate alpha-synuclein pathology. Dr. Borghammer has a dual role as a clinician and researcher, bridging fundamental science with patient care. His expertise ensures that cutting-edge imaging technologies translate seamlessly into improved diagnostics and therapeutic strategies for neurodegenerative disorders. Widely published in top-tier scientific journals, Dr. Borghammer’s research has positioned him as a global authority in his field. His contributions continue to drive forward both clinical practice and fundamental understanding of Parkinson’s disease and related disorders.

Prof. Enza Maria Valente is a renowned neuroscientist and medical geneticist specializing in thegenetics of Parkinson’s disease and other movement disorders. Currently aProfessor of Medical Genetics at the University of Pavia, she leads theNeurogenetics Research Center and Genetic Diagnostic Lab at the IRCCS Mondino Foundation. Her pioneering research has advanced the understanding of key genes such as PINK1, LRRK2, PARK2, and SNCA, and the genetic basis of cerebellar malformations. Supported by prestigious grants, including an ERC Starting Grant, Dr. Valente has authored numerous influential publications and collaborates internationally on projects such as ASAP GP2. She is a prominent figure in neurogenetics, contributing to global efforts to unravel the genetic basis of neurodegenerative disorders.

Prof. Thomas Gasser is a Professor of Neurology and Director of the Department of Neurodegenerative Diseases at the Hertie-Institute for Clinical Brain Research, University of Tübingen, Germany. He also serves as Chairman of the Board of the Center of Neurology at the University of Tübingen and Speaker of the German Center for Neurodegenerative Diseases in Tübingen. Dr. Gasser’s research focuses on the genetic and molecular basis of Parkinson’s disease, dystonia, and other movement disorders, aiming to identify genes and loci involved in these conditions and analyse their functional consequences. His work seeks to uncover drug targets and biomarkers for disease risk and progression. He has authored over 200 peer-reviewed papers and approximately 100 reviews and book contributions. Dr. Gasser has received several prestigious research grants and honours, including the prestigious “2024 Breakthrough Prize in Life Sciences”, the world’s most highly endowed science prize.

Prof. Elke Kalbe has been a Professor of Medical Psychology at the University Hospital of Cologne since 2015. She studied psychology, linguistics, and phonetics at the University of Bonn and earned her PhD in psychology from the University of Bielefeld. Following her PhD, she worked as an Assistant Professor in the Neurology department of the University Clinic of Cologne. In 2009, she joined the Institute for Neuroscience and Medicine (INM-III) at the Research Center Jülich, and in 2010, she became a Professor of Psychological Gerontology and Head of the Center for Neuropsychological Diagnosis and Intervention at the University of Vechta. Her research focuses on the neuropsychology of Parkinson’s disease and Alzheimer’s disease, mild cognitive impairment, dementia, cognition-based interventions, cognitive tests, and functional brain imaging. She has authored several scientific papers and received the Prize for Brain Research in Geriatrics from the University Witten/Herdecke in 2011, as well as a research award from the German Parkinson Society in 2014.

Prof. Roger Barker is a distinguished neurologist and neuroscientist at the University of Cambridge, where he serves as Professor of Clinical Neuroscience and Consultant in Neurology at Addenbrooke’s Hospital Cambridge. For over two decades, Prof. Barker has run research that seeks to better define the clinical heterogeneity of Parkinson’s and Huntington’s disease. This has helped him define the best way by which to take new therapies into the clinic. In this respect he has been heavily involved in gene and cell based trials for patients with these conditions and currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD, following on from an earlier Medical Research Council funded trial using similar tissue in HD. He is part of a global initiative (GFORCE-PD) that is seeking to take stem cells to trial in these disorders.

Dr. Kenneth Marek, MD, is President and senior scientist at the Institute for Neurodegenerative Disorders. Dr. Marek earned his medical degree from Yale University, was trained in internal medicine and neurology at the Johns Hopkins School of Medicine, and received further training as a post-doctoral fellow in neurochemistry at the Institute of Neurology, Queens Square, London. Dr. Marek’s major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson’s, Alzheimer’s and related neurodegenerative disorders. His specific interest is in in vivo neuroreceptor imaging biomarkers. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek is the principal investigator of several ongoing multi-center international studies, including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Associated Risk Syndrome (PARS) study. Dr Marek serves as a special scientific advisor to The Michael J. Fox Foundation. He has held leadership roles in several organizations focused on neurodegenerative disorders and has been the recipient of numerous grants to support his research. He was recently awarded the Robert A. Pritzker Prize for Leadership in Parkinson’s Research. He also was a co-founder of Molecular NeuroImaging, LLC, and is now an employee and owner at Invicro, a company providing discovery and clinical neuroimaging research services.

Dr. Andrew Singleton is a leading neuroscientist and geneticist at the National Institute on Aging, NIH, where he directs the Laboratory of Neurogenetics. His research focuses on understanding the genetic underpinnings of neurodegenerative diseases, particularly Parkinson’s disease and related disorders. Dr. Singleton has made significant contributions to the identification of genetic risk factors for Parkinson’s and other neurodegenerative diseases through large-scale genomic studies. He leads several international collaborations aimed at advancing personalized medicine and therapeutic development. As a scientific advisor to the Michael J. Fox Foundation, Dr. Singleton is instrumental in shaping Parkinson’s research.

Prof. Kathrin Brockmann is a senior physician and head of the Parkinson’s outpatient clinic at the department of neurodegenerative diseases at the Center of Neurology, University of Tübingen. As research group leader at the Hertie Institute for Clinical Brain Research in Tübingen, Dr. Brockmann’s main areas of research are large-scale longitudinal studies to better understand the different phases of neurodegeneration as well as symptom development and progression in PD. In this context, she focuses on stratification of patients according to genetic architecture and the underlying pathologic processes, reflected by profiles of their biomaterials. This approach allows her to directly translate research findings into the clinic and to introduce people with PD to pathway-specific therapies.

Prof. Vincenzo Bonifati is a leading neurologist and researcher specializing in the genetics of neurodegenerative disorders. He is a professor at the Erasmus University Medical Center in Rotterdam, where he directs research on the molecular basis of Parkinson’s disease and related conditions. Dr. Bonifati’s ground-breaking work has led to the identification of key genetic mutations associated with Parkinson’s, significantly advancing the understanding of its hereditary forms. He collaborates on international studies aimed at uncovering new pathways for diagnosis and therapy and has authored numerous influential publications in the field. Dr. Bonifati is widely recognized for his contributions to neurogenetics and translational research.

Dr. Pille Taba is a renowned neurologist and professor of Neurology at the University of Tartu in Estonia. Her clinical and research expertise focuses on movement disorders, particularly Parkinson’s disease and parkinsonism, as well as autoimmune and infectious influences on the nervous system. Dr. Taba is actively involved in international collaborations and serves as a member of multiple professional organizations dedicated to neurology and movement disorders. She has authored numerous scientific publications and contributes to advancing diagnostic and therapeutic strategies for Parkinson’s and related conditions. Dr. Taba is also a sought-after speaker at international conferences, sharing insights from her extensive clinical and academic experience.

Dr. Asha Kishore is a distinguished neurologist and expert in movement disorders and currently serves as Director at the Aster Centre for Parkinson and Movement Disorders. She was a former Senior Professor in Neurology, Head of the Comprehensive Care Centre for Movement Disorders, and Director at the Sree Chitra Tirunal Institute for Medical Sciences and Technology in India. Her research focuses on Parkinson’s disease, deep brain stimulation, and neuro-rehabilitation, with a particular interest in exploring innovative therapeutic strategies for movement disorders. Dr. Kishore has made significant contributions to clinical research and is actively involved in advancing care for Parkinson’s patients in India and globally. She has authored numerous publications and is a recognised leader in neurology, frequently presenting her work at international conferences and contributing to collaborative research initiatives worldwide

Prof. Andrea Kühn is a professor and head of the movement disorders and neuromodulation unit at the Department of Neurology at the Charité – Universitätsmedizin Berlin. Her clinical and research expertise centers on Parkinson’s disease and other movement disorders, with a focus on deep brain stimulation (DBS) and neuromodulatory therapies. Dr. Kühn has significantly advanced the understanding of brain networks involved in motor control and the mechanisms underlying DBS. She is involved in multiple international research collaborations and has authored numerous high-impact publications in the field of neurology. Dr. Kühn’s work bridges clinical practice and translational research, contributing to improved therapeutic strategies for movement disorders.

Prof. Brit Mollenhauer is a professor in the Department of Neurology at University Medical Center Göttingen and chief physician at Paracelsus-Elena-Clinic Kassel, both in Germany. She has developed a translational research program focusing on biomarker development for early and prodromal diagnosis, for the progression of Parkinson’s disease and related deep phenotyping. Prof. Mollenhauer has launched several observational cohorts, including the De Novo PD (DeNoPa) cohort based in Kassel to better understand the natural history of PD and variants of manifest disease as well as their prodromal stages. Her interdisciplinary research program spans the pathophysiology, epidemiology, and deep phenotyping of PD.

Prof. Joaquim Ferreira is a leading neurologist and clinical researcher specializing in Parkinson’s disease and movement disorders. He is a professor at the Faculty of Medicine, University of Lisbon, and the head of the Clinical Pharmacology Unit at the Institute of Molecular Medicine. Prof. Ferreira’s research focuses on the clinical development of new therapies for Parkinson’s disease and related neurodegenerative disorders, with expertise in pharmacology and clinical trials. He has played a key role in international research collaborations, including the FAIR-PARK II study, and has authored numerous scientific publications. As an expert in movement disorders, Prof. Ferreira is actively involved in shaping treatment strategies and advancing patient care.

Prof. Werner Poewe is Professor of Neurology and Director of the Department of Neurology at Medical University Innsbruck, Austria. Professor Poewe’s main research interests in the field of movement disorders are focused on differential and early diagnosis of Parkinson’s disease, its natural history and pharmacological treatment. He has been involved in the steering committees of numerous drug trials in different stages of Parkinson’s disease for the past two decades and has authored and co-authored numerous original articles and reviews in the field of movement disorders. Professor Poewe is listed among top 1% of ‚highly cited researchers in neuroscience (Clarivate Web of Science  2021).

Prof. Lena Burbulla is a Professor for Metabolic Biochemistry of Neurodegenerative Diseases at Ludwig Maximilians University Munich, Germany. Her research focuses on uncovering key molecular pathways driving neurodegeneration by studying rare genetic diseases, with the aim of identifying shared mechanisms and novel therapeutic targets. Using genetic Parkinson’s disease as a model, she investigates disease processes in specific neuronal subtypes over time to better understand age-dependent vulnerability. Combining advanced biomolecular techniques with patient-derived models, Prof. Burbulla’s work bridges fundamental neuroscience and translational research to develop targeted strategies for neurodegenerative disease treatment.

Dr. Manu Sharma is a trained genetic epidemiologist and neuroscientist. His expertise integrates fields of neurogenetics, genetic epidemiology, statistical genetics, and bioinformatics to understand the genetic architecture of neurodegenerative diseases. Since 2013, he is leading the Centre for Genetic Epidemiology within the Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany. He is the coordinator of the Luxembourg-German Indian Alliance on Neurodegenerative diseases and Therapeutics (Lux-GIANT). Dr Sharma has made significant contributions to the understanding of neurodegenerative diseases, particularly in relation to Alzheimer’s and Parkinson’s diseases. His research explores the molecular and cellular mechanisms of these disorders, and he actively drives innovative approaches to improving diagnosis and treatment options.

Prof. Dr. Christine Klein has been trained as and still a practising neurologist specialized on Parkinson’s Disease. After her studies she joined the Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA as research fellow and spends regular research visits at the Movement Disorders Unit of the Toronto Western Hospital, Toronto, Canada. She has been awarded the Oppenheim Award of the German Dystonia Foundation (2000), the Parkinson Award of the German Neurological Society (2001), the Lichtenberg Career Development Award of the Volkswagen Foundation (2005), the Heinrich Pette Award of the German Neurological Society, the Derek-Denny Brown Award of the American Neurological Association (2008), the Schilling Career Development Award of the Hermann and Lilly Schilling Foundation (2009) and the Lübeck BioMedTec Award (2014).

Dr. Alexis Elbaz is a distinguished neurologist and epidemiologist, holding both a medical degree in Neurology and a PhD in Epidemiology. He serves as Director of Research at Inserm U1018, part of the Centre for Research in Epidemiology and Population Health, while also practicing as a physician at Hôpital de la Salpêtrière in France. His research explores motor decline in aging populations, the effects of aging on neurological health, and the complex interplay between genetic and environmental factors in Parkinson’s disease. Dr. Elbaz has also contributed internationally as a visiting or affiliate scientist at renowned institutions such as the Mayo Clinic and University College London.

Dr. Céline Galvagnion-Büll is an Associate Professor in Biophysical Pharmacology at the University of Copenhagen’s Department of Drug Design and Pharmacology. She earned her PhD in Chemistry from Université Pierre et Marie Curie in 2011. Her research focuses on understanding the molecular mechanisms underlying neurodegenerative diseases, particularly the role of lipid disruptions in Parkinson’s Disease. By employing interdisciplinary approaches that combine biology and biophysics, her work aims to elucidate how changes in lipid metabolism contribute to protein aggregation and neuronal cell death. Dr. Galvagnion-Büll has been recognized with several grants, including the Novo Nordisk Foundation’s Hallas-Møller Emerging Investigator grant and the Carlsberg Foundation Young Researcher Fellowship. In addition to her research, she coordinates the “Biochemistry and Cellular Biology” course for the Bachelor’s program in Medicinal Chemistry

Dr. Mohamed Salama is an associate professor at the Institute of Global Health and Human Ecology at the American University in Cairo, Egypt. He obtained his medical degree (MBBCH) from Mansoura University in 1999, followed by a Master’s in Toxicology in 2006. Through a DAAD scholarship, he earned his PhD in Neurotoxicology in 2011 in collaboration with Philipps University in Marburg, Germany. Dr. Salama leads the Egyptian Longitudinal Study of Aging, aiming to understand the various determinants of health and disease in aging populations. His research focuses on identifying both intrinsic factors, such as genetics, and extrinsic factors, like environmental exposures, that influence health outcomes in the elderly. As an Atlantic Fellow for Equity in Brain Health at the Global Brain Health Institute, he emphasizes the importance of studying diverse populations to address dementia and promote brain health globally.

Dr. Edward Fon is a neurologist and researcher at McGill University, specializing in Parkinson’s disease and movement disorders. He is the Scientific Director at the Montreal Neurological Institute (MNI) and a full Professor in Neurology. Dr. Fon also directs the McGill National Parkinson Foundation Centre of Excellence and the Quebec Parkinson Network. His research focuses on the molecular mechanisms of dopamine neuron degeneration in Parkinson’s, particularly the roles of genes like α-Synuclein, parkin, and PINK1. He has received numerous prestigious awards for his work, including the CIHR Clinician-scientist award and the EJLB Foundation Scholar Award.

Dr. Niels Janssen works as an assistant professor at the Alzheimer Centrum Limburg (Maastricht University). His research focuses on dementia risk reduction with a specific focus on reducing inequity in prevention. Niels is currently involved in several projects, including the co-coordination of a public health campaign on brain awareness. Furthermore, he is project coordinator of a multicenter RCT on examining the (cost)effectiveness of an innovative lifestyle intervention in the memory clinic (LIGHT).

Prof. Dr. Nobutaka Hattori is a Chairman and Professor of the Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan. Since 2020, he is the Team Leader, Neurodegenerative Disorders Collaborative Laboratory, RIKEN Center for Brain Science. He was involved in research about molecular mechanisms of Parkinson’s disease (PD) since 1989. He found decrease in the amount of complex I in the substantia nigra of PD patients. More recently, his collaborators and he identified the disease gene for an autosomal recessive form of young onset familial PD, and named the gene as “parkin”. This is the second form of familial PD in which the disease gene was identified. In addition, they found that the gene product, parkin was direct linked to ubiquitin- proteasome pathway as an ubiquitin ligase. This discovery suggested that protein degradation system was involved in the pathogenesis of not only monogenic form of PD but also sporadic PD.

Prof. Jochen Klucken is a neurologist, neuroscientist, and FNR-PEARL Chair of Digital Medicine at the University of Luxembourg. He leads the Digital Medicine Research Group (dMed) at the Luxembourg Centre for Systems Biomedicine (LCSB), the Luxembourg Institute of Health (LIH), and the Centre Hospitalier de Luxembourg (CHL). His research focuses on advancing personalized digital healthcare solutions and evaluating the medico-socio-economic benefits of innovative digital medical devices and services. As a co-leading rapporteur of the EU taskforce for harmonized evaluation of digital medical devices, Prof. Klucken is shaping frameworks for their clinical assessment. With extensive experience in start-ups and clinical research, he bridges public and private sector efforts to develop sustainable, data-driven healthcare technologies, fostering innovation in digital medicine.

Prof. Dr. Anne Grünewald studied Biotechnology at the University of Applied Sciences Jena before specializing in genetics of movement disorders during her doctoral studies with Prof Christine Klein at University of Lübeck (2005-2008). During a research stay in the laboratory of Prof Anthony Schapira at University College London, she got fascinated with the multifaceted functions of mitochondria. To deepen her understanding of mitochondria, she visited the mitochondrial disease expert Prof. Carolyn Sue at Sydney University in 2010. She then pursued postdoctoral studies at the Wellcome Trust Centre for Mitochondrial Research, Newcastle University, under Prof Doug Turnbull, where she explored the role of mtDNA maintenance impairments in Parkinson’s disease (PD) brain tissue. This work led to a successful application for a 5-year ATTRACT career development award from the Luxembourg Research Fund. In 2016, Anne joined the Luxembourg Centre for Systems Biomedicine, where she established her own group focused on mitochondrial signaling in PD. Since 2021, she is a Full Professor in Neuroscience at the University of Luxembourg. Her team is specialized in mitochondrial function and mtDNA (single-cell) analysis techniques, which are applied to iPSC-derived neuronal and glia models. Among other involvements, Prof. Grünewald is a principal investigator (PI) in the FNR CORE projects MitoDefinePD and RareCom, which deal with mitochondrial metabolism and function in disease and the FNR INTER grant mitoERsgnl, which explores a potential link between mtDNA homeostasis and calcium signaling. Moreover, she leads the interdisciplinary AUDACITY project “MITO-MANIAK” at the Institute of Advanced Studies of the University of Luxembourg. In total, she has acquired ~8 million EUR of grant support. Prof. Grünewald is a member of the University of Luxembourg Leadership Academy and the Gender Equality Committee of the University of Luxembourg.

Prof. Dr. Nico Diederich is a clinical neurologist, he has studied at the Universities of Homburg/Saar and Bonn (Germany) and had trained in neurology at the University of Cologne (Germany) and at the Rush University, Chicago (USA). He has written the doctoral thesis on the involvement of the sympathetic and parasympathetic nervous system in the genesis of hypertension and his “Habilitation” on clinical non motor symptoms in Parkinson’s disease (PD), with special emphasis on hallucinations and sleep fragmentation.  He is a “Privat-Dozent” for Neurology at the University of Cologne (Germany) and regularly teaches at this University. He is also a Visiting Assistant Professor at Rush University and annually returns for mini-sabbaticals to this institution. His clinical practice is at the CHL in Luxembourg-City (Luxembourg). While he treats there inpatients and outpatients with any neurological condition, his main focus of clinical and scientific interest are movement disorders and sleep disorders. In particular, he is involved in longitudinal studies of various non motor symptoms in early stages of PD and in network analysis of these symptoms. In particular he focuses on visual, olfactory and sleep dysfunctions.

Dr. Frank Hertel is the head of the national department of neurosurgery at the Centre Hospitalier de Luxembourg (CHL). Besides his medical training as a specialist in neurosurgery, he has a background in electrical engineering, which enables extraordinary close collaborations with engineers and computer scientists. After his university studies in medicine, he trained in Neuropathology at the University Clinic of Mainz, Germany (Prof. H.H. Goebel) from 1994 to 1995, followed by a residency in Neurosurgery in Mainz (Prof. A. Perneczky) and Trier (Prof. K. Faulhauer). He specialised in Neurosurgery in 2001. He was the head of the neurosurgical department at the SHG Hospital Idar-Oberstein (Germany) from 2007 to 2008, before he became head of the national department in Luxembourg. He has close to fifteen years of experience in deep brain stimulation, with over 500 implantations performed so far. In 2003, he initiated a still ongoing collaboration with Prof. P. Gemmar from the Department of computer science at Trier University of Applied Sciences (Germany). The focus of this collaboration is research and development in the field of computer aided neurosurgery with a “close to the operating room” focus. Results of this successful collaboration have been licenced to leading companies in the field (Medtronic, Inomed).

Enrico Glaab is an Assistant Professor, Deputy Course Director, and Principal Investigator in the Biomedical Data Science Group at the University of Luxembourg. He holds a PhD in Bioinformatics from the University of Nottingham, where his doctoral research focused on innovative techniques for analyzing functional genomics data. Dr. Glaab’s career began as a Research Associate at the Luxembourg Centre for Systems Biomedicine in 2011, where he contributed to key interdisciplinary research projects integrating computational biology and systems medicine. In 2015, he advanced to the role of Research Scientist, where he led efforts in developing bioinformatics tools and methodologies to tackle complex biomedical challenges. By 2017, Dr. Glaab was promoted to Senior Research Scientist and Deputy Course Director, mentoring students and junior researchers while expanding educational curricula in bioinformatics. Since 2018, Dr. Glaab has served as Assistant Professor, where he directs cutting-edge research aimed at applying computational techniques to personalized medicine, drug discovery, and disease modeling. His work focuses on integrating diverse biological data to better understand disease mechanisms and improve clinical decision-making. As a Principal Investigator, Dr. Glaab continues to lead high-impact research, shaping the future of biomedical data science both in academia and beyond.

Anja Leist is Full Professor in Public Health and Ageing and Vice-Head of the Institute for Research on Socio-Economic Inequality at the University of Luxembourg. She also serves as Special Advisor to the Rector on the topic of research assessment. Her research focuses on cognitive ageing and dementia from a social and behavioural risk reduction perspective and has been funded, among others, by the European Research Council (CRISP, grant agreement no. 803239) and the Luxembourg National Research Fund. Specifically, together with her team, Anja identified relevant contextual-level influences on cognitive ageing and dementia related to inequalities in educational opportunity, socioeconomic conditions, and sex/gender, using machine learning and methods for causal inference in observational data. Another research project MCI-BIOME, where Anja is co-PI and which is funded by the University of Luxembourg’s Institute for Advanced Studies, investigates the relationships between sociodemographic and modifiable risk factors for dementia, the gut microbiome, and Mild Cognitive Impairment. Anja is elected Fellow of the Gerontological Society of America and co-founder of the non-profit organisation World Young Leaders in Dementia a.s.b.l. (WYLD) network that facilitates careers of young professionals in dementia globally. She serves as expert reviewer, panel member for funders, and on several Scientific Advisory Boards, for instance of the national dementia prevention programme pdp. She has given numerous invited talks on the topics of brain health, dementia risk reduction, and AI in disease prevention. She co-leads getbrainhealthy.org, a platform to promote brain health at the workplace.

Dr. Brice Appenzeller Brice M.R. Appenzeller is head and founder of the Human Biomonitoring Research Unit (HBRU) – Luxembourg Institute of Health, and associate Professor adjunct at the University of Luxembourg. He obtained his PhD in Biology-Health-Environment from the Faculty of Pharmacy of Nancy, France in 2002. After 6 years working in clinical and forensic toxicology, he founded HBRU in 2008 and started the research thematic on the biomonitoring of human exposure to pollutants. His research activity is mainly centred on the study of the chemical exposome in human populations, with a special focus on vulnerable categories (e.g. pregnant women, children), the identification of the determinants of exposure, and the consequences of exposure on human health. He is also interested in the study of mechanisms of incorporation of chemicals in hair, and in using this matrix for hormonal profiling to investigate hormonal disruption associated with various stressors. He is author of >100 scientific articles in international journal. He is expert member in several work groups for the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and past member of the scientific council of the French Ministry of Agriculture. He is member of the Society of hair testing (SoHT) and of the International Society of Exposure Sciences (ISES). He is board member of SoHT since 2012, and vice-president since 2023.